太平洋医药日报（20260122）：第一三共ADC新药R-DXd在华获突破性疗法认定

Investment Rating - The industry rating is "Neutral" for the biopharmaceutical sector, indicating a balanced outlook with expected returns in line with the market [3][9]. Core Insights - The report highlights that Daiichi Sankyo's ADC drug R-DXd has received breakthrough therapy designation in China for treating platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer in adults who have previously received bevacizumab [5]. - The pharmaceutical sector experienced a decline of 0.42% on January 22, 2025, underperforming the CSI 300 index by 0.43 percentage points, ranking 29th among 31 sub-industries [4]. - Key performers in the market included offline pharmacies (+1.70%), pharmaceutical distribution (+0.90%), and hospitals (+0.40%), while other biopharmaceuticals (-1.08%) and medical device sectors (-0.44%) lagged [4]. Summary by Sections Market Performance - On January 22, 2025, the pharmaceutical sector's performance was -0.42%, underperforming the CSI 300 index by 0.43 percentage points, with offline pharmacies and medical distribution showing positive growth [4]. Company News - Boteng Co. (300363) expects revenue of 3.35-3.50 billion yuan in 2025, a year-on-year increase of 11%-16%, with a net profit forecast of 80-105 million yuan [6]. - Jinkai Technology (688356) anticipates revenue of 315 million yuan in 2025, a growth of 38.71%, with net profit expected to reach 60-66 million yuan, reflecting a significant increase of over 100% [6]. - Yiling Pharmaceutical (002603) projects a net profit of 1.20-1.30 billion yuan for 2025, indicating a turnaround from losses in the previous year [6].